Seismic's Impact platform systematically integrates machine learning, structural biology, protein engineering, and translational immunology to invent novel biologics and optimize properties with significantly improved efficiency and scale over conventional therapeutics discovery, according to the company. With this new approach, Seismic is accelerating a pipeline of biologics targeting dysregulated adaptive immunity to treat autoimmune diseases.

The series A financing will support Seismic's further advancement toward the clinic of its first two lead drug programs, one targeting immunoglobulin-mediated autoimmunity and the other targeting cell-mediated autoimmunity.

Seismic Therapeutic is a biotechnology company integrating machine learning across the entire biologics discovery process to accelerate immunology drug development.

The series A round was led by Lightspeed Venture Partners with other investors.